Biotech Analysts Brayer & Schimmer, along with Dr. Rosenfeld, Professor of Pediatrics at Stanford University School of Medicine, discuss Achondroplasia and the clinical comparisons (efficacy/safety) between BridgeBio Pharma’s infigratinib and BioMarin Pharmaceutical’s Voxzog on an Analyst/Industry conference call to be held on June 4 at 10 am. Webcast Link
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
- BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
- BridgeBio: Acoramidis data show boost in serum TTR levels in CV outcomes at ISA
- BridgeBio price target lowered to $47 from $51 at UBS
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue